Literature DB >> 21215693

Enhanced antibody-dependent cellular phagocytosis by chimeric monoclonal antibodies with tandemly repeated Fc domains.

Hiroaki Nagashima1, Michiko Ootsubo, Mizuki Fukazawa, Sotaro Motoi, Shu Konakahara, Yasuhiko Masuho.   

Abstract

We previously reported that chimeric monoclonal antibodies (mAbs) with tandemly repeated Fc domains, which were developed by introducing tandem repeats of Fc domains downstream of 2 Fab domains, augmented binding avidities for all Fcγ receptors, resulting in enhanced antibody (Ab)-dependent cellular cytotoxicity. Here we investigated regarding Ab-dependent cellular phagocytosis (ADCP) mediated by these chimeric mAbs, which is considered one of the most important mechanisms that kills tumor cells, using two-color flow cytometric methods. ADCP mediated by T3-Ab, a chimeric mAb with 3 tandemly repeated Fc domains, was 5 times more potent than that by native anti-CD20 M-Ab (M-Ab hereafter). Furthermore, T3-Ab-mediated ADCP was resistant to competitive inhibition by intravenous Ig (IVIG), although M-Ab-mediated ADCP decreased in the presence of IVIG. An Fcγ receptor-blocking study demonstrated that T3-Ab mediated ADCP via both FcγRIA and FcγRIIA, whereas M-Ab mediated ADCP exclusively via FcγRIA. These results suggest that chimeric mAbs with tandemly repeated Fc domains enhance ADCP as well as ADCC, and that Fc multimerization may significantly enhance the efficacy of therapeutic Abs.
Copyright © 2010 The Society for Biotechnology, Japan. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21215693     DOI: 10.1016/j.jbiosc.2010.12.007

Source DB:  PubMed          Journal:  J Biosci Bioeng        ISSN: 1347-4421            Impact factor:   2.894


  7 in total

1.  Trial Watch: Monoclonal antibodies in cancer therapy.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Jessica Zucman-Rossi; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

Review 2.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

3.  Enhancement of antibody functions through Fc multiplications.

Authors:  Qun Wang; Yan Chen; Mark Pelletier; Romana Cvitkovic; Jessica Bonnell; Chien-Ying Chang; Adem C Koksal; Ellen O'Connor; Xizhe Gao; Xiang-Qing Yu; Herren Wu; C Kendall Stover; William F Dall'Acqua; Xiaodong Xiao
Journal:  MAbs       Date:  2017-01-19       Impact factor: 5.857

4.  Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.

Authors:  Dennis R Goulet; Adam Zwolak; James A Williams; Mark L Chiu; William M Atkins
Journal:  Proteins       Date:  2019-11-20

5.  Effect of trastuzumab interchain disulfide bond cleavage on Fcγ receptor binding and antibody-dependent tumour cell phagocytosis.

Authors:  Mami Suzuki; Ayaka Yamanoi; Yusuke Machino; Michiko Ootsubo; Ken-ichi Izawa; Junya Kohroki; Yasuhiko Masuho
Journal:  J Biochem       Date:  2015-08-08       Impact factor: 3.387

6.  Fc Binding by FcγRIIa Is Essential for Cellular Activation by the Anti-FcγRIIa mAbs 8.26 and 8.2.

Authors:  Bruce D Wines; Halina M Trist; Sandra Esparon; Rachael E Impey; Graham A Mackay; Robert K Andrews; Tatiana P Soares da Costa; Geoffrey A Pietersz; Ross I Baker; P Mark Hogarth
Journal:  Front Immunol       Date:  2021-10-25       Impact factor: 7.561

7.  In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies.

Authors:  Dapeng Li; Robert J Edwards; Kartik Manne; David R Martinez; Alexandra Schäfer; S Munir Alam; Kevin Wiehe; Xiaozhi Lu; Robert Parks; Laura L Sutherland; Thomas H Oguin; Charlene McDanal; Lautaro G Perez; Katayoun Mansouri; Sophie M C Gobeil; Katarzyna Janowska; Victoria Stalls; Megan Kopp; Fangping Cai; Esther Lee; Andrew Foulger; Giovanna E Hernandez; Aja Sanzone; Kedamawit Tilahun; Chuancang Jiang; Longping V Tse; Kevin W Bock; Mahnaz Minai; Bianca M Nagata; Kenneth Cronin; Victoria Gee-Lai; Margaret Deyton; Maggie Barr; Tarra Von Holle; Andrew N Macintyre; Erica Stover; Jared Feldman; Blake M Hauser; Timothy M Caradonna; Trevor D Scobey; Wes Rountree; Yunfei Wang; M Anthony Moody; Derek W Cain; C Todd DeMarco; Thomas N Denny; Christopher W Woods; Elizabeth W Petzold; Aaron G Schmidt; I-Ting Teng; Tongqing Zhou; Peter D Kwong; John R Mascola; Barney S Graham; Ian N Moore; Robert Seder; Hanne Andersen; Mark G Lewis; David C Montefiori; Gregory D Sempowski; Ralph S Baric; Priyamvada Acharya; Barton F Haynes; Kevin O Saunders
Journal:  Cell       Date:  2021-06-18       Impact factor: 66.850

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.